Flurpiridaz F 18 (FLYRCADO™) is an intravenous (IV) radioactive diagnostic drug being developed by GE Healthcare and Lantheus Medical Imaging for use in positron emission tomography (PET) myocardial perfusion imaging (MPI) to detect coronary artery disease (CAD). In September 2024, flurpiridaz F 18 was approved in the USA for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected CAD to evaluate for myocardial ischemia and infarction. This article summarizes the milestones in the development of flurpiridaz F 18 leading to this first approval for use in PET MPI in adult patients to evaluate for myocardial ischemia and infarction.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40256-024-00718-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Flurpiridaz F 18: First Approval.
Am J Cardiovasc Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Flurpiridaz F 18 (FLYRCADO™) is an intravenous (IV) radioactive diagnostic drug being developed by GE Healthcare and Lantheus Medical Imaging for use in positron emission tomography (PET) myocardial perfusion imaging (MPI) to detect coronary artery disease (CAD). In September 2024, flurpiridaz F 18 was approved in the USA for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected CAD to evaluate for myocardial ischemia and infarction. This article summarizes the milestones in the development of flurpiridaz F 18 leading to this first approval for use in PET MPI in adult patients to evaluate for myocardial ischemia and infarction.
View Article and Find Full Text PDFEvaluation of myocardial perfusion imaging techniques and artificial intelligence (AI) tools in coronary artery disease (CAD) diagnosis through multi-criteria decision-making method.
Cardiovasc Diagn Ther
December 2024
Operational Research Center in Healthcare, Near East University, Nicosia, Turkey.
Background: Cardiovascular diseases (CVDs) continue to be the world's greatest cause of death. To evaluate heart function and diagnose coronary artery disease (CAD), myocardial perfusion imaging (MPI) has become essential. Artificial intelligence (AI) methods have been incorporated into diagnostic methods such as MPI to improve patient outcomes in recent years.
View Article and Find Full Text PDFAssessment of Myocardial Perfusion in Patients After CABG: An Update and Clinical Implications.
Semin Nucl Med
December 2024
Mid-America Heart Institute and the Saint-Lukes Health System, University of Missouri - Kansas City, Kansas, MO. Electronic address:
Stress radionuclide myocardial perfusion imaging (MPI) has been well-established as a useful modality for assessing the status of the coronary circulation in post-coronary artery bypass graft (CABG) patients. CABG by itself escalates progression of atherosclerosis or thrombosis in bypassed native coronary arteries. In most cases MPI will be employed in post-CABG patients who are experiencing symptoms.
View Article and Find Full Text PDFMyocardial perfusion imaging in a case of cardiac strangulation: A novel approach to detect pacemaker-induced ischemia.
Ann Pediatr Cardiol
November 2024
Department of Nuclear Medicine and PET-CT, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India.
Article Synopsis
- Cardiac strangulation is a rare issue in children that can occur years after epicardial pacemaker implantation due to the pacemaker wires compressing the heart and its blood vessels.
- A case was reported where a patient experienced this condition 8 years post-implantation, with imaging revealing significant compression of the left anterior descending artery.
- The patient underwent successful pacemaker reimplantation after myocardial perfusion imaging confirmed ischemia caused by this compression, highlighting the effectiveness of MPI in asymptomatic cases.
Comparative evaluation of a novel [F] F-Labeled PET tracer XTR004 against [N] ammonia in myocardial perfusion imaging for coronary artery disease.
Eur J Nucl Med Mol Imaging
December 2024
Department of Nuclear Medicine, Peking Union Medical College Hospital. Chinese Academy of Medical Science & Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
Aims: This study aimed to evaluate image quality, myocardial perfusion, and diagnostic performance of a novel [F]F-labeled PET tracer, XTR004 PET, myocardial perfusion imaging (MPI) compared with [N]Ammonia (NH) PET MPI.
Methods And Results: Forty-seven patients with suspected or known coronary artery disease (CAD) were prospectively enrolled to undergo one-day rest/ATP-stress XTR004 and NH electrocardiograph-gated PET imaging within 2 weeks. Among them, twenty-six patients underwent invasive coronary angiography (ICA), and nineteen were identified with flow-limited CAD (stenosis ≥ 70%).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!